Alvotech (NASDAQ: ALVO) announced on June 8, 2026 that the U.S. Food and Drug Administration has accepted for review a Biologics License Application for AVT16, the company's proposed interchangeable biosimilar referencing Entyvio® (vedolizumab) lyophilized vial for intravenous administration. The acceptance triggers a formal review clock and positions AVT16 as a potential lower-cost alternative in the biologic gut-health treatment landscape — a category with growing relevance to the broader functional gastrointestinal market.
Vedolizumab is a gut-selective humanized monoclonal antibody that inhibits the α4β7 integrin, blocking lymphocyte trafficking to inflamed intestinal mucosa. Its mechanism of action is distinct from systemic immunosuppressants, making it a preferred clinical endpoint benchmark in moderate-to-severe inflammatory bowel disease (IBD) trials. An interchangeability designation, if ultimately granted, would allow pharmacists in most U.S. states to substitute AVT16 for the reference biologic without prescriber intervention — a regulatory threshold that biosimilar developers prize for its downstream formulary and market-access implications.
For operators and formulators in the functional foods and nutraceutical space, the advance of gut-targeted biologics into biosimilar competition signals sustained institutional validation of the intestinal immune axis as a therapeutic and wellness frontier. The IBD patient population, estimated in the tens of millions in the U.S. alone, overlaps meaningfully with consumers actively seeking digestive-health functional foods, postbiotic formats, and microbiome-modulating ingredients. As clinical medicine validates gut-immune mechanisms at the biologic level, structure-function claims built on gut-barrier integrity and mucosal support gain corresponding scientific credibility in the supplement channel. Brands positioned in the gut-health and microbiome category may find the regulatory momentum around gut-selective biologics provides a rising-tide narrative for ingredient storytelling.
Alvotech, headquartered in Reykjavik, Iceland, specializes in the development and contract manufacture of biosimilar medicines and has built a pipeline spanning multiple therapeutic categories. The FDA's BLA acceptance does not constitute approval, but confirms the application is sufficiently complete to proceed to substantive review. The agency will evaluate analytical, clinical, and manufacturing data to assess biosimilarity and, separately, whether the interchangeability standard has been met. Operators tracking regulatory and ingredient-approval trends should note that interchangeable biosimilar designations remain relatively rare and represent the highest bar in the FDA's biosimilar framework.
The broader context for the nutraceutical trade is competitive: as pharmaceutical-grade gut-immune therapies become more accessible through biosimilar pathways, consumer expectations for evidence-based digestive-health products will likely rise in parallel. Finished-formulation brands with peer-reviewed clinical support, standardized extract documentation, and transparent dosing disclosures will be best positioned to meet that elevated bar.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.